Chinese Journal of Tissue Engineering Research ›› 2016, Vol. 20 ›› Issue (2): 167-172.doi: 10.3969/j.issn.2095-4344.2016.02.003

Previous Articles     Next Articles

Expression of jumonji domain-containing histone demethylase 2 and estrogen-related receptor alpha in postmenopausal osteoporosis

Tang Hong-yu1, 2, Dong Lu-jue3, Huo Shao-chuan3, Guo Cheng3, Zhou Chi1, 2, Chen Jian-fa1, Liu Yong3, Wang Hai-bin1, 2   

  1. 1Orthopedics Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; 2the National Key Research Laboratory of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; 3Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
  • Received:2015-10-16 Online:2016-01-08 Published:2016-01-08
  • Contact: Wang Hai-bin, M.D., Chief physician, Professor, Doctoral supervisor, Orthopedics Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; the National Key Research Laboratory of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
  • About author:Tang Hong-yu, Master, Physician, Orthopedics Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China; the National Key Research Laboratory of Orthopedics, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China
  • Supported by:

    the National Natural Science Foundation of China, No. 81373655; Guangdong Provincial Science and Technology Plan Projects, No. 2013B021800226

Abstract:

 

BACKGROUND: Jumonji domain-containing histone demethylase (JMJD) can promote osteoblast differentiation, and estrogen-related receptor alpha (ERRα) can promote osteoblast differentiation and increase bone formation. However, little is reported on the association between postmenopausal osteoporosis and JMJD and ERRα.
OBJECTIVE: To study the changes in the JMJD2 family expression in patients with postmenopausal osteoporosis.

METHODS: Postmenopausal patients with osteoarthritis of the hip scheduled for total hip arthroplasty, aged 50-70 years, were enrolled, including 10 postmenopausal osteoporosis patients (experimental group) and 10 patients with no postmenopausal osteoporosis (control group). During the arthroplasty, the cancellous bone specimens from the femoral head were collected. Then, immunohistochemistry and western blot assay were used to detect expression of histone demethylase (JMJD2A, JMJD2B), histone methylation (H3K9me3, H3K36me3) and ERRα.

RESULTS AND CONCLUSION: In the experimental group, the expressions of JMJD2A, JMJD2B and ERRα were from weakly positive to positive; these expressions were significantly lower in the experimental group than the control group (P < 0.05). The expressions of H3K9me3 and H3K36me3 were significantly higher in the experimental group than the control group (P < 0.05). These findings indicate that the expression of JMJD2A and JMJD2B is consistent with the expression of ERRα in the patients with postmenopausal osteoporosis, and JMJD is likely to serve as an antagonistic enzyme of osteoporosis.